Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Opsens Inc T.OPS

Alternate Symbol(s):  OPSSF

OpSens Inc. is engaged in physiological measurements such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and in transcatheter aortic valve replacement (TAVR) in the structural heart market. The Company supplies an optical-based pressure guidewire (OptoWire), a guidewire used in the TAVR procedure (SavvyWire) and a wide range of miniature optical sensors to measure pressure and temperature to be used in a wide range of applications that can be integrated into other medical devices.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

Lift off !

I heard that lift off is scheduled at 9:30 ! Hold on to your hats. Have a nice day everyone !  rate and reply

TAVR receives

FDA approval . Congrats all .   rate and reply

New Press Release - OPSENS ANNOUNCES FDA CLEARANCE FOR THE SAVVYWIRE(TM) FOR USE IN TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) PROCEDURES

QUEBEC CITY, Sept. 15, 2022 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has received 510(k) regulatory clearance...read article.

Conference

Any company participating in conferences are generally positive. Especially attending one in America with a market of their size. Hopefully they attract investors or someone to buy them out.   rate and reply

Just two days notice

Opsens will participate in a conference in Boston and will present the savvywire. They may have good news to share then. Good luck to all  rate and reply

New Press Release - OpSens to Participate in the Transcatheter Cardiovascular Therapeutics Conference (TCT) in Boston September 16-19, 2022

OpSens to unveil the SavvyWire, the first and only sensor-guided Transcatheter Aortic Valve Replacement (TAVR) solutionOpSens will present its latest innovations including the SavvyWire, at booth 743, and sponsor a scientific breakfast Satellite Program presented by an expert panel of leading...read article.

RE:About Opsen growth

If I'm correct, FDA approval could be any day now? GL  rate and reply

About Opsen growth

Ten years ago revenues at Opsen were $ 8 462 000 and the cost of sales were  $ 2 740 000 for a gross margin of $ 2 740 000  or 32 % and the bottom line a loss of $ 1 930 000  Last year...read more

I love this company and the ''huge'' growth in the making...

But  I just want to ''pintpoint''  some observation I made  on the ''work force '' inside the plant! I just have been looking at the ''Google...read more

RE:RE:RE:RE:Ops price target

Hi Nadia, yes that price target is all over found too. Raymond James actually issued that target of $6.00 about one year ago as well. Rahul has been following another stock I really like pink.v.   rate and reply

RE:RE:RE:Ops price target

After verification, I confirm that $6 seems to be the highest target at the moment.    rate and reply

6$ not 7.88$

That 7.88$ came from my TD Webbroker  they corrected it to 6$ sorry about that  rate and reply

RE:RE:Ops price target

I'd stick with $6.00. I've had that as a target from RJ for awhile and it seems clear that he simply reiterated it. No idea where $7.88 came from but I would forget about it for now. When we...read more

RE:Ops price target

I wondered about that as well. Maybe he made a mistake ? marketbeat.com 9/8/2022 Raymond James   Rahul Sarugaser   Reiterated Rating...read more

Ops price target

Hey I'm not following, I read the article from Raymond James. I see a price target of $6.00, assuming it's 6 dollars canadian bc the article states ops:tsx.   rate and reply

Raymond James - cantechletter.com

RJ maintains their bullish take for Opsens . By Jayson MacLean Published on September 8, 2022 Last Updated on September 8, 2022 Filed under:   All posts, Analysts...read more

Sorry correction

He just reiterated the stock to 7.88$ My bad sorry.  rate and reply

Raymond James new target price

Rahul Sarugaser an analyst from Raymond James lifted the target price today to $7.88 . I feel way better now! Glta  rate and reply

What the hell happened yesterday?

A 12% hair cut with huge volume then the day after  it goes up 4% with higher than average volume. Is it a short attack? Is it people in the know trying to get in cheap before the big pop...read more